A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports)

Background We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC). Methods Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual a...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2008-09, Vol.246 (9), p.1235-1239
Main Authors: Torres-Soriano, Mitzy E., García-Aguirre, Gerardo, Kon-Jara, Verónica, Ustariz-Gonzáles, Orlando, Abraham-Marín, Maura, Ober, Michael D., Quiroz-Mercado, Hugo
Format: Article
Language:English
Subjects:
Adult
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Chorioretinitis - diagnosis
Chorioretinitis - drug therapy
Female
Fluorescein Angiography
Humans
Injections
Male
Medicine
Medicine & Public Health
Middle Aged
Ophthalmology
Pigment Epithelium of Eye - pathology
Pilot Projects
Retinal Disorders
Serum
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity
Vitreous Body
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC). Methods Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment. Results All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment. Conclusions Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.
ISSN:0721-832X
1435-702X
DOI:10.1007/s00417-008-0856-x